EATONTOWN, N.J., Dec. 13 /PRNewswire-FirstCall/ -- Osteotech, Inc.
(Nasdaq: OSTE) announced today that the Food and Drug Administration ("FDA")
has cleared its 510(k) application for the Company's new GraftCage(TM) ACX,
for use in the thoracic and lumbar spine, which the Company expects to launch
in the first quarter of 2006. The GraftCage(TM) ACX is designed for strength
and ease of insertion by surgeons and can be implanted utilizing existing
Osteotech instrumentation. The GraftCage(TM) ACX features titanium markers to
facilitate intra-operative and post-operative radiographic assessments and an
opening for the insertion of bone grafting materials, including a new form of
the recently introduced Xpanse(TM) Bone Insert, to allow for maximum graft
exposure. This new version of Xpanse(TM) Bone Insert is expected to be
launched concurrently with the launch of the GraftCage(TM) ACX.
Sam Owusu-Akyaw, Osteotech's President and Chief Operating Officer,
stated, "The GraftCage(TM) ACX is the first in a series of new products from
Osteotech manufactured from PEEK material that we expect to introduce into the
market over the course of 2006. These products will participate in the
overall spinal interbody market, which, in 2005, is approximately $558 million
of which PEEK products represent approximately $221 million. Used together,
the Xpanse(TM) Bone Insert and GraftCage(TM) ACX create a unique vertebral
body spacer allowing for maximum end-plate contact, structural support,
osteoinductivity and osteoconductivity, which are the four key functional
requirements in order to achieve a successful fusion."
The GraftCage(TM) ACX is intended to replace a collapsed, damaged, or
unstable vertebral body in the thoracic or lumbar spine. It is indicated for
a partial or total vertebrectomy in cases of tumor or trauma related damage to
the vertebral body. The GraftCage(TM) ACX is intended to restore the height
of a collapsed vertebral body.
Certain statements made in this press release that are not historical
facts contain forward-looking statements (as such are defined in the Private
Securities Litigation Reform Act of 1995) regarding the Company's future
plans, objectives and expected performance. Any such forward-looking
statements are based on assumptions that the Company believes are reasonable,
but are subject to a wide range of risks and uncertainties and, therefore,
there can be no assurance that the actual results may not differ materially
from those expressed or implied by such forward-looking statements. Factors
that could cause actual results to differ materially include, but are not
limited to, the failure of the FDA to clear the Company's additional 510(k)
submissions for its GraftCage(TM) Products, the continued acceptance and
growth of current products and services, differences in anticipated and actual
product and service introduction dates, the ultimate success of those products
in their marketplace, the impact of competitive products and services, the
availability of sufficient quantities of suitable donated tissue and the
success of cost control and margin improvement efforts. Certain of these
factors are detailed from time to time in the Company's periodic reports
(including the Annual report on Form 10-K for the year ended December 31, 2004
and the Form 10-Q for each of the first three quarters of 2005) filed with the
Securities and Exchange Commission. All information in this press release is
as of December 13, 2005 and the Company undertakes no duty to update this
information.
Osteotech, Inc., headquartered in Eatontown, New Jersey, is a leading
provider of human bone and bone connective tissue for transplantation and an
innovator in the development and marketing of biomaterial and implant products
for musculoskeletal surgery. For further information regarding Osteotech or
this press release, please go to Osteotech's website homepage at
http://www.osteotech.com and to Osteotech's Financial Information Request Form
website page at http://www.osteotech.com/finrequest.htm.
SOURCE Osteotech, Inc.
 back to top
Related links:
http://www.osteotech.com
Company News On-Call:
http://www.prnewswire.com/comp/668050.html
CONTACT:
Michael J. Jeffries of Osteotech, Inc.,
+1-732-542-2800
|
